Outlook Wealth Advisors LLC Invests $305,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Outlook Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 428 shares of the biopharmaceutical company’s stock, valued at approximately $305,000.

A number of other hedge funds have also recently made changes to their positions in REGN. State Street Corp grew its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after buying an additional 61,277 shares during the last quarter. International Assets Investment Management LLC grew its position in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the period. Charles Schwab Investment Management Inc. increased its position in Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after buying an additional 11,499 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock worth $357,945,000 after acquiring an additional 2,270 shares in the last quarter. Finally, Swiss National Bank raised its holdings in Regeneron Pharmaceuticals by 0.6% during the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after acquiring an additional 2,000 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $693.23 on Friday. The business has a 50 day simple moving average of $744.16 and a 200-day simple moving average of $954.41. The company has a market capitalization of $76.18 billion, a P/E ratio of 17.15, a PEG ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Analysts Set New Price Targets

Several brokerages recently weighed in on REGN. Evercore ISI reduced their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. JPMorgan Chase & Co. lowered their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Finally, UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $1,130.00 to $738.00 in a report on Thursday. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.